Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome

Area of Science:

• Nephrology
• Hematology
• Immunology

Background:

• Atypical hemolytic-uremic syndrome (aHUS) is a severe genetic disorder characterized by complement-mediated thrombotic microangiopathy.
• Current treatments like plasma exchange offer only transient hematologic improvements without addressing the systemic disease.

Purpose of the Study:

• To evaluate the efficacy and safety of eculizumab in adult and adolescent patients with atypical hemolytic-uremic syndrome.
• To assess the impact of eculizumab on hematologic parameters, renal function, and quality of life.

Main Methods:

• Two prospective Phase 2 trials involved patients aged 12+ with aHUS receiving eculizumab for 26 weeks, followed by extension phases.
• Trial 1 focused on patients with low platelet counts and renal damage; Trial 2 included patients with renal damage and stable platelet counts during plasma exchange.

Main Results:

• Eculizumab treatment led to significant increases in platelet counts and achieved thrombotic microangiopathy event-free status in 80% of patients in Trial 2.
• Patients experienced time-dependent improvements in estimated glomerular filtration rate (GFR), with some discontinuing dialysis.
• Eculizumab was associated with improved health-related quality of life and no observed cumulative toxicity or serious infection-related adverse events.

Conclusions:

• Eculizumab effectively inhibits complement-mediated thrombotic microangiopathy in aHUS.
• The therapy demonstrates significant, time-dependent improvements in renal function and quality of life for aHUS patients.
• Eculizumab represents a promising therapeutic option for atypical hemolytic-uremic syndrome.